Submitted by Carmen Smith on Thu, 23/01/2020 - 11:49
A new type of scan that involves magnetising molecules allows doctors to see in real-time which regions of a breast tumour are active, according to research at the University of Cambridge and published in Proceedings of the National Academy of Sciences.
This is one of the most detailed pictures of the metabolism of a patient’s breast cancer that we’ve ever been able to achieve. It’s like we can see the tumour ‘breathing’
Kevin Brindle
This is the first time researchers have demonstrated that this scanning technique, called carbon-13 hyperpolarised imaging, can be used to monitor breast cancer. The team based at the Cancer Research UK Cambridge Institute and the Department of Radiology, University of Cambridge, tested the technique in seven patients with various types and grades of breast cancer before they had received any treatment.
They used the scan to measure how fast the patients’ tumours were metabolising a naturally occurring molecule called pyruvate, and were able to detect differences in the size, type and grade of tumours – a measure of how fast growing, or aggressive the cancer is. The scan also revealed in more detail the ‘topography’ of the tumour, detecting variations in metabolism between different regions of the same tumour.
Professor Kevin Brindle, lead researcher from the institute, said: “This is one of the most detailed pictures of the metabolism of a patient’s breast cancer that we’ve ever been able to achieve. It’s like we can see the tumour ‘breathing’. “Combining this with advances in genetic testing, this scan could in the future allow doctors to better tailor treatments to each individual, and detect whether patients are responding to treatments, like chemotherapy, earlier than is currently possible”.
Breast cancer is the most common type of cancer in the UK, with around 55,000 new cases each year. 80% of people with breast cancer survive for 10 years or more, however for some subtypes, survival is much lower. Professor Charles Swanton, Cancer Research UK’s chief clinician, said: “This exciting advance in scanning technology could provide new information about the metabolic status of each patient’s tumour upon diagnosis, which could help doctors to identify the best course of treatment.
“And the simple, non-invasive scan could be repeated periodically during treatment, providing an indication of whether the treatment is working. Ultimately, the hope is that scans like this could help doctors decide to switch to a more intensive treatment if needed, or even reduce the treatment dose, sparing people unnecessary side effects.”
The research was supported by Cancer Research UK Cambridge Institute and The Mark Foundation for Cancer Research.
To read the full article, please visit the University of Cambridge website.
